You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201341 - 201350 of 207728 results
  1. Microfluidic Processing of Leukocytes for Molecular Diagnostic Testing

    SBC: GPB Scientific, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Microfluidic Processing of Leukocytes for Diagnostics Testing Summary/Abstract: New tests to quantify the numbers and functional states of key leukocyte types from blood samples offer enhanced determination and personalization of clinical diagnosis, prognosis, and treatment response. For example, labeling of gt30 cell surface and intracellular target molecules ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. QuitAdvisorOB: A tool for delivering smoking cessation guidance to pregnant women

    SBC: HEALTH DECISION TECHNOLOGIES, LLC            Topic: NIDA

    DESCRIPTION (provided by applicant): The long-term objective of this project is to provide a smoking-cessation intervention tool for health care providers in prenatal settings. Smoking during pregnancy is a significant public health issue. The prevalence of smoking in women of child-bearing age generally ranges between 17 and 35 percent worldwide, and is heavily influenced by maternal age, ethnici ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Novel Class for Opioid Drugs

    SBC: ALGYNOMICS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): The mu-opioid receptor (MOR) is the primary target for opioid analgesics. While opioids are the most frequently used and effective analgesics for the treatment of moderate to severe clinical pain, their prolonged use leads to reduced efficacy and a number of adverse side effects, including post dosing-induced hyperalgesia and analgesic tolerance. MOR induces an ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Pilot PK Study with a Novel Nicotine Replacement Therapy for Smoking Cessati

    SBC: PHARMACEUTICAL PRODUCTIONS, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): The proposed Proof of Concept Study seeks Phase I STTR funding to support a novel nicotine replacement therapy (NRT) pilot pharmacokinetic (PK) trail in healthy smokers. Very little by way of product development has occurred in the NRT field despite scientists' and clinicians' pleas for improved NRTs, specifically for a faster-acting NRT that resemble ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Medical Sensor Applications of Tunnel Magnetoresistance (TMR)

    SBC: Koronis Biomedical Technologies Corp.            Topic: NIDCD

    DESCRIPTION (provided by applicant): Koronis Biomedical Technologies (KBT) proposes to develop a novel tunneling magnetoresistance (TMR) sensor for use in medical devices. TMR technology delivers improvements in magnetic sensor size, sensitivity, and noiserejection that represent an opportunity to significantly enhance the performance of a variety of medical devices that currently rely on traditio ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Auditory Processing Training: A Novel Treatment for Sound Hypersensitivities in A

    SBC: Cognionics, Inc.            Topic: NIDCD

    DESCRIPTION (provided by applicant): The autism spectrum disorders [ASDs] encompass a set of neurodevelopmental conditions defined by abnormalities in behavior and social communicative skills. It is presently estimated that there are more than 1.5 millionautistic individuals in the US alone. Almost 50% of children with autism are completely non-verbal, and less than 10% achieve independent living ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. RADIOGRAPHIC CONTRAST TO DIFFERENTIATE CAVITATED FROM NON-CAVITATED DENTAL CARIES

    SBC: FIREFLY HEALTH INNOVATIONS NE, INC.            Topic: NIDCR

    DESCRIPTION (provided by applicant): This project relates directly to the PHS 2011-2, Omnibus Solicitation for SBIR/STTR Grant Application page NIDCR 110: Development of instrumentation for early caries detection and comparison studies on specificity andselectivity with respect to current clinical practice. The proposed test is intended to enable dentists to differentiate between cavitated and ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. AAV Mediated Gene Transfer to the CNS for MPS I

    SBC: REGENX BIOSCIENCES, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Mucopolysaccharidosis type I (MPS I) is an autosomal recessive storage disease caused by the absence of a-L-iduronidase (IDUA), resulting in systemic accumulation of glycosaminoglycan (GAG) storage materials, hepatosplenomegaly, skeletal dysplasias, cardiopulmonary obstruction, progressive neurologic impairment and death by age 15. MPS I is currently treated b ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Iron functionalized silica as oral phosphate binder to treat hyperphosphatemia

    SBC: PDX PHARMACEUTICALS, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Hyperphosphatemia is universal to end stage chronic kidney disease patients and a majority of dialysis patients totaling of 400,000 in the US and 2 million worldwide. Current oral phosphate binders to treat hyperphosphatemia still have many drawbacks, including a high risk of calcification, high costs ( 2100- 6500 per patient a year), low-to-moderate efficacy, ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Bacterially-Secreted GLP-1 Induced Reprogramming of Intestinal Cells as a Treatme

    SBC: BIOPANCREATE, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The product that will result from the proposed SBIR program, a consortium collaboration between BioPancreate (a small business) and Cornell University, will be an orally-administered insulin-replacement therapy for bothtype-1 and type-2 diabetes mellitus, utilizing a novel live biotherapeutic product that reprograms host intestinal stem cells into pancreatic ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government